Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($0.33), $0.15 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $178.49 million versus the consensus estimate of $186.76 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.